BLA Submitted for Denosumab

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Benjamin J. Golas, MD

June 30th 2025

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Daniella Natanov;Sharon Koehler

SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

Related Content

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

Benjamin J. Golas, MD

June 30th 2025

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Daniella Natanov;Sharon Koehler

SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia